The U.S. Food and Drug Administration has approved Juvisync (sitagliptin and simvastatin), the first combination drug to treat type 2 diabetes and high cholesterol in one tablet. Read more.
FDA approves first combination tablet to treat type 2 diabetes and high cholesterol
*Online Bonus Content: This has not been peer reviewed. The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal.
